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Abstract: Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal 
osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, 
hence outcomes. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent 
dosing schedules. Ibandronate is a potent, nitrogen-containing bisphosphonate which, uniquely, can be administered either orally, 
monthly, or as an intravenous injection, every 3 months. A positive impact for adherence has been observed with a reduction in the 
bisphosphonate dosing frequency. Anti-fracture efficacy of the various currently available regimens of ibandronate is documented in 
randomized controlled clinical trials, non-inferiority studies, meta-analyses and real-life settings studies. The present paper summarizes 
the pharmacology, efficacy and tolerability of oral and intravenous ibandronate, when administered with extended dosing intervals, 
in postmenopausal osteoporosis.
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Introduction
Postmenopausal osteoporosis may develop in women 
following either naturally-occurring or surgically-
induced menopause. Osteoporosis is characterized by 
low bone mass and microarchitectural deterioration, 
leading to compromised bone strength and an 
increase in the risk of fracture. Osteoporosis is 
clinically diagnosed as an history of fragility fracture 
and may also be diagnosed by a report of low bone 
mineral density (BMD), after dual-energy x-ray 
absorptiometry (DXA) scanning. DXA measures 
areal BMD is influenced by bone mass as well as the 
degree of mineralization of the bone matrix. DXA 
does not specifically measure bone microarchitecture 
or distinguish between the trabecular and cortical 
components of bone. Recently, clinical risk factors were 
shown to be significantly associated with the risk of 
hip and other osteoporotic fractures, independently 
of BMD measurement. The combination of clinical 
risk factors and BMD provides higher specificity 
and sensitivity than either alone, for fracture 
risk assessment. These results provide the basis 
for the integrated use of validated clinical risk 
factors, in men and women, to improve fracture 
risk prediction.1 Recently developed non-invasive 
imaging techniques, such as computed tomography 
and magnetic resonance imaging, can be used to 
quantitatively assess micro- and macro-structure 
and, therefore, provide a more detailed report on 
the condition of the bone.2,3 However, due to cost 
and availability, these advanced techniques are not 
used in routine clinical practice.
Although routine DXA screening in women aged at 
least 65 years or postmenopausal women younger than 
65 years with associated risk factors is recommended, 
osteoporosis is often not diagnosed until the patient 
suffers a fragility fracture. Osteoporosis is a risk 
factor for fracture just as hypertension is for stroke. 
The most common fractures are those of the vertebrae, 
proximal femur and distal forearm. Fractures of the 
vertebrae and proximal femur may lead to chronic 
pain, disability and death. Within the first year post-
hip fracture, 80% of patients are unable to carry 
out at least one independent activity of daily living 
and the associated mortality rate is 20%.4 Vertebral 
fractures also cause significant complications including 
back pain, height loss, kyphosis and death. These 
physical manifestations of osteoporosis can lead to 
psychological symptoms, most notably depression 
and loss of self-esteem.
Therefore, postmenopausal osteoporosis is a silent, 
chronic disease with serious consequences if not 
diagnosed and treated effectively. The socio-economic 
impact of this disease will continue to grow with the 
globally-increasing elderly population. It is estimated 
that 1 in 3 women over 50 will experience osteoporotic 
fractures and by 2050, the worldwide incidence of hip 
fracture in women is projected to increase by 240%.5,6 
In the US, costs associated with osteoporotic fractures 
were estimated to be $17 billion in 2005, increasing by 
up to 50% by 2025.7 The direct costs associated with 
osteoporotic fractures in Europe were estimated to 
be €31.7 billion in 2000 and are expected to increase 
to €76.7 billion in 2050.8
Included within the above costs are acute fracture care 
(hospitalization, surgery, joint prostheses, etc.), chronic 
fracture care (rehabilitation) and therapeutic options for 
the treatment of postmenopausal osteoporosis, which 
include calcium and vitamin D, strontium ranelate, 
selective estrogen-receptor modulators, calcitonin, 
teriparatide and bisphosphonates.9
The nitrogen-containing bisphosphonates, available 
for oral and intravenous (i.v.) administration, are one 
of the current drugs of choice. Ibandronate (Bonviva®) 
is a nitrogen-containing bisphosphonate, available in 
the US and EU since 2005 for monthly oral dosing 
and by quarterly i.v. injection since 2006.10,11
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
The molecular structure of all bisphosphonates 
includes a P-C-P (Phosphorous-Carbon-Phosphorous) 
backbone; the bone mineral affinity and antiresorptive 
potency is derived from the chemical moieties at the 
R1 and R2 positions (R = residues at C). Ibandronate 
(3-[N-methyl-N-pentyl] amino-1-hydroxypropane-1, 
1-diphosphonic acid, monosodium salt, monohydrate; 
molecular weight 359.24) has one of the most potent 
structural arrangements, with a hydroxyl group at the 
R1 position enhancing affinity for bone and a tertiary 
nitrogen group at the R2 position that significantly 
increases potency compared with the non-nitrogen-
containing bisphosphonates (e.g. etidronate, clodronate).12 
All nitrogen-containing bisphosphonates work by 
inhibiting farnesyldiphosphate synthase. The rank 
order of potency for in vitro inhibition is: alendronate, 
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ibandronate, risedronate and zoledronate.13 The rank 
order of potency of in vivo inhibition of bone resorption 
in rates is: alendronate, risedronate, ibandronate and 
zoledronate.13–16
The pharmacokinetic profile of ibandronate has 
previously been described in detail by Barrett and 
colleagues.17 Therefore, presented here is an overview 
of the key points.
Consistent with other oral bisphosphonates, oral 
ibandronate (pKa 2.0, 6.3 and 10.5) is poorly absorbed 
from the gastrointestinal (GI) tract. Oral bioavailability 
is estimated to be 0.63%. It is likely that poor 
absorption of oral bisphosphonates is due to their 
negative charge at physiological pH. Paracellular 
transport is considered to be the most likely route 
of absorption, as transcellular transport through the 
epithelial membrane is reduced due to the polarity. 
Pharmacokinetics following oral administration show 
both inter- and intra-subject variability (area under 
curve [AUC]: 70%; coefficient of variation: ~46%). 
Nevertheless, oral ibandronate is quickly absorbed, 
mean peak plasma concentrations (C
max
) are achieved 
by approximately 1 hour.
Similar to the oral administration of other 
bisphosphonates, to maximize bioavailability ibandronate 
should be taken after an overnight fast of at least 
6 hours and 60 minutes before the first food or drink 
(other than water) of the day. Plasma concentrations 
of ibandronate are noticeably reduced when taken 
immediately following food (90%: AUC0-∞ ratio: 
11%; 90% CI = -9%, -32%).17
Following absorption and initial systemic exposure, 
40%–50% of ibandronate is distributed and bound 
to bone, the remainder is excreted unchanged in 
the urine. The volume of distribution (VD) for 
ibandronate administered intravenously is 90–368 L 
in healthy subjects and 103 L in postmenopausal 
women with osteopenia. This high VD reflects the 
distribution of ibandronate into bone throughout the 
body. In rats, receiving daily subcutaneous injections 
of ibandronate in doses ranging from 0.003 to 
0.3 mg/kg/day for 9 days, concentration of ibandronate 
increased dose-dependently in mandible, femur and 
lumbar vertebrae, with similar concentration per 
bone at each dose level, ranging from values below 
quantification limit (low dose) up to approximately 
10 ng ibandronate/mg bone dry weight (high dose). 
There was a relatively similar bisphosphonate uptake 
between the femur and lumbar vertebrae bones, 
whereas the uptake in the jaw was statistically smaller 
with regard to the absolute values, suggesting no 
preferential bisphosphonate uptake in the jaw.18
Ibandronate is not metabolised. No metabolites 
were produced when ibandronate was incubated 
in vitro with rat, dog and human liver microsomes 
or when oral or i.v. ibandronate was administered to 
humans or animals.17 Even at concentrations greater 
than 1000-fold than those found clinically, there is a 
lack of affinity between ibandronate and the major 
cytochrome P450 isoforms. Metabolic stability and 
urinary excretion of the unchanged compound are 
characteristics associated with all bisphosphonates.
Within 24 hours, unabsorbed oral ibandronate 
is excreted in the faeces and ~50%–60% of i.v. 
ibandronate is excreted unchanged in the urine, 
absorbed oral ibandronate is also excreted unchanged 
in the urine. However, the half-life of ibandronate 
is multiphasic, following initial elimination in the 
first 24 hours, the elimination half-life (t1/2) of 
ibandronate is 10–60 hours due to elimination from 
the bone and subsequent elimination from the kidney. 
The calculated renal clearance (CLR) of ibandronate 
is 54–112 mL/min (in healthy postmenopausal women), 
which accounts for 50%–60% of the total clearance, 
with the remainder distributed into bone. Over the 
following years ibandronate is released from the bone 
and excreted renally. Thus, the CLR of ibandronate, 
and other bisphosphonates, is dependent on renal 
function, resulting in CLR being reduced in renally 
impaired patients.
It is acknowledged that all patients receiving multiple 
medications, such as those with postmenopausal 
osteoporosis, are potentially at risk for drug-drug 
interactions. However, ibandronate does not inhibit or 
alter cytochrome P450 (CYP) metabolism, as previously 
discussed. Therefore, pharmacokinetic studies have 
shown that ibandronate does not interact with tamoxifen, 
melphalan or prednisolone. A minor increase (20%) in 
the AUC of ibandronate in combination with ranitidine 
has been noted, although this was attributable to an 
increase in gastric pH and was not considered to be 
clinically relevant.
The efficacy of intermittent administration of 
subcutaneous and intravenous ibandronate has been 
demonstrated in various animal models (rat, dog, 
minipig and monkey). In these animals, ibandronate 
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administered subcutaneously or intravenously, with 
extended intervals between doses reduces bone 
turnover, increases bone mineral density and maintains 
bone quality in a dose-dependent manner. Furthermore, 
studies in rats and dogs compared in continuous and 
intermittent treatments schedules indicate similar 
efficacy when the same cumulative dose is applied over 
the duration of the study. These studies with ibandronate 
illustrate the concept that the total cumulative dose of 
bisphosphonate administered determines the response, 
independent of whether the dose is given daily or less 
frequently in a given time period. Important factors for 
determining efficacy and the magnitude of response 
are the doses given, the length of the interval between 
doses and the underlying bone turnover rate.19
The pharmacodynamics of bisphosphonates, in 
human, are measured by assessment of BMD and 
bone turnover markers. In a study of postmenopausal 
osteopenic women (n = 180), daily oral ibandronate 
0.25–5 mg increased BMD of the spine and proximal 
femur and reduced bone turnover markers (osteocalcin 
and urinary c-telopeptide of type 1 collagen [CTX]) 
versus placebo.20 The 2.5 mg daily dose was 
considered to be the most effective. Monthly oral 
ibandronate (50–150 mg), given to postmenopausal 
women with osteoporosis (n = 144), substantially 
reduced serum and urinary CTX from baseline by 
day 91 (30 days after the final dose; p  0.001 for 
the 100 mg and 150 mg doses versus placebo).21 The 
data showed highly significant associations between 
pharmacokinetic parameters of ibandronate and the 
clinical response in bone mass and bone turnover.22 
The change from baseline in serum and urinary CTX in 
the area under the effect curve (day 1–91) indicated 
a dose-response relationship. A dose-ranging study of 
ibandronate 0.25–2 mg administered every 3 months 
by i.v. injection (n = 126) reported increases in BMD 
of the spine and proximal femur and reduced bone 
turnover markers (osteocalcin and CTX) in a dose-
dependent manner versus placebo.23 A study of 
healthy postmenopausal women (n = 73) receiving 
i.v. ibandronate (1 mg or 2 mg) or no treatment 
assessed the levels of serum CTX and osteocalcin at 
19 consecutive time points.24 A rapid onset of treatment 
effect was reported with the nadir for serum CTX 
reached 7 days after drug administration. At 2 weeks 
after drug administration, the serum levels of CTX had 
started to rise, reaching –16% and –20% immediately 
before the second drug administration (Day 84). 
Osteocalcin decreased more slowly reaching a nadir 
after 5 months. Considering these data alongside that 
reported for other studies discussed later, it appears 
that maintaining bone turnover reduction within the 
premenopausal range is important for anti-fracture 
efficacy rather than reported fluctuations during 
treatment.
With the aim of identifying practical dosing regimens 
for further clinical study, an extensive modelling and 
simulation project was completed with ibandronate.25,26 
A simplified kinetic-pharmacodynamic (K-PD) model, 
developed from a 4-compartment pharmacokinetic-
pharmacodynamic model, was designed to accurately 
predict the pharmacodynamic response, excretion of 
urinary CTX, following administration of varying 
doses of ibandronate. The model included an 
allowance for the effects of supplemental calcium 
therapy and allowed simultaneous fitting of i.v. and 
oral ibandronate data. The residual (i.e. 1 month after 
dosing) level of median decrease in urinary CTX 
following administration of several different once-
monthly oral ibandronate doses over 12 months was 
assessed using the K-PD model. Simulations from 
the 100 virtual trials, which each included 250 virtual 
patients, demonstrated substantial reductions in the 
median residual levels of urinary CTX with 100 mg 
and 150 mg monthly oral ibandronate at 3, 6, 9 
and 12 months. The efficacy and safety of these 
two monthly ibandronate doses were then assessed 
in clinical trials.
clinical studies
Monthly oral ibandronate (150 mg) and quarterly i.v. 
injection ibandronate (3 mg) are the regimens used in 
clinical practice for the treatment of postmenopausal 
osteoporosis.10,11 Although daily oral ibandronate 
(2.5 mg) has also received a favourable response 
from the regulatory authorities, this regimen is not 
available for prescription.
Oral and i.v. ibandronate have been studied extensively 
for prevention and treatment of postmenopausal 
osteoporosis. The key efficacy studies are detailed 
below.
Oral ibandronate
Oral daily ibandronate (2.5 mg) was investigated 
for the prevention of bone loss in postmenopausal 
ibandronate in the management of postmenopausal osteoporosis
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women without osteoporosis. BMD at the lumbar 
spine and hip were significantly increased (3.1% and 
1.8%, respectively; p  0.0001 versus placebo) after 
24 months.27 In ambulatory postmenopausal women, 
aged 45–60 years, with baseline lumbar spine BMD 
T-score  -1.0 and  -2.5 and baseline T-score  -2.5 
at the total hip, trochanter and femoral neck, and no 
prior vertebral or low-trauma osteoporotic fractures 
at baseline, monthly oral ibandronate (150 mg) 
induced larger increases in lumbar spine BMD after 
1 year compared with subjects receiving placebo 
(3.7% vs. -0.4%; p  0.0001). After 3 months, median 
serum C-terminal telopeptide of type I collagen levels 
were reduced by 55% in the ibandronate group 
compared with 4% in the placebo group. At 1 year, 
88.2% of the participants treated with ibandronate 
achieved increases in lumbar spine BMD  0% 
compared with 38.6% of subjects receiving placebo.28 
Treatment regimens were well tolerated in both the 
ibandronate treated and placebo groups suggesting 
that monthly ibandronate therapy is an appropriate 
option to prevent bone loss in postmenopausal women 
with low bone mass.
The anti-fracture efficacy of daily oral ibandronate 
(2.5 mg) and intermittent oral ibandronate (20 mg 
every other day for 12 doses every 3 months) was 
assessed in postmenopausal osteoporotic women in 
the iBandronate Osteoporosis trial in North America 
and Europe (BONE).29 The two ibandronate regimens 
were associated with significant reductions in the risk 
of vertebral fractures versus placebo (62%, p = 0.0001 
and 50%, p = 0.0006, respectively). BONE was the 
first study to demonstrate an anti-fracture effect 
with an intermittently administered bisphosphonate. 
A significant reduction in non-vertebral fractures was 
not seen in the overall population (mean total hip BMD 
T-score -1.7). However, subgroup analyses including 
women at higher risk for fracture showed significant 
reductions in non-vertebral fracture risk (femoral neck 
BMD T-score  -3.0: 69%, p = 0.012; lumbar spine 
BMD T-score  -2.5 and a history of clinical fractures 
in the past 5 years: 62%, p = 0.025).29,30 Retrospective 
analysis from the BONE study demonstrated that, in 
addition to being effective in significantly reducing 
the risk of new vertebral fractures of all severities, 
oral daily ibandronate has a pronounced effect on 
the more severe, most clinically relevant, vertebral 
fractures: a significant and sustained reduction of 
59% in the relative risk of combined new moderate 
and severe vertebral fractures was observed at years 1 
(P = 0.0164), 2 (P = 0.0004), and 3 (P  0.0001).31
Following the demonstration of anti-fracture 
efficacy with daily ibandronate the focus became 
extending the dose-free interval to develop a more 
convenient regimen. As identified through modelling 
and simulation, previously discussed, 50 + 50 mg 
(single doses on consecutive days), 100 mg and 
150 mg doses of monthly ibandronate were studied in 
the Monthly Oral iBandronate In LadiEs (MOBILE) 
study.32,33 The 150 mg dose produced the greatest 
gains in BMD versus daily ibandronate (2.5 mg) 
at 2 years (lumbar spine BMD: 6.6% versus 5.0%, 
respectively, p  0.001). All regimens reduced serum 
CTX to within the premenopausal range by 3 months 
and maintained the lower levels throughout the 
2-year study. A 3-year long-term extension (LTE) to 
MOBILE is currently ongoing. An interim analysis at 
1 year (3 years on treatment) has shown that patients 
receiving continuous monthly ibandronate (100 mg 
or 150 mg) in the MOBILE LTE continued to gain 
lumbar spine BMD and at the hip.34 The reduced 
levels of serum CTX reported during MOBILE have 
been maintained in the LTE.
In addition to the above studies focusing solely on 
ibandronate, the efficacy of monthly oral ibandronate 
has been compared with weekly alendronate with 
regards to BMD gains at the lumbar spine and total 
hip (primary endpoint; MOTION study).35 Based 
on the pre-specified criteria, non-inferiority of both 
regimens was reported at 1 year for changes in BMD 
(lumbar spine: 5.1% and 5.8%, respectively; total hip: 
2.9% and 3.0%, respectively). Increases in trochanter 
and femoral neck BMD were also similar with both 
regimens. Although the reduction in bone markers was 
faster with ibandronate, changes in both serum CTX 
and amino-terminal propeptide of type I procollagen 
(P1 NP) were similar in the two treatment arms.36 The 
AUC values (%*days) for serum CTX were –27,595.7 
for ibandronate and –27,924.2 for alendronate, and 
for P1 NP, –20,057.9 for ibandronate and –20,193.2 
alendronate.
intravenous ibandronate
A randomized anti-fracture efficacy study of i.v. 
ibandronate injections, 1 mg and 0.5 mg once every 
3 months, was conducted at a similar time to 
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BONE.37 Although an almost significant trend 
toward a reduction in the incidence of fracture was 
observed with ibandronate compared with placebo, 
the magnitude of fracture reduction did not reach 
statistical significance. However, ibandronate produced 
dose-dependent increases in lumbar spine BMD and 
decreases in biochemical bone markers relative to 
placebo. It was, also shown, that a 2 mg ibandronate 
i.v. regimen provides significantly greater BMD 
increases and significantly greater suppression of 
bone resorption markers than the 1 mg dose used in the 
fracture prevention study,23,38,39 with no significant 
difference in the overall number of adverse event in 
the ibandronate group compared with the placebo 
group. Therefore, it was determined that either higher 
doses of intermittent ibandronate or a shorter dose-
free interval would be required to achieve fracture 
protection.
To evaluate this hypothesis, the Dosing IntraVenous 
Administration (DIVA) study assessed the efficacy of 
2 mg every 2 months and 3 mg quarterly ibandronate 
i.v. injections compared with daily oral ibandronate 
(2.5 mg).40,41 The design of DIVA was the same as 
MOBILE, with the exception of the different route 
of ibandronate administration. At 2 years, both i.v. 
regimens produced improvements in spinal BMD that 
were superior to oral ibandronate (2.5 mg; p  0.001). 
In addition, BMD gains at all hip sites were greater 
in the i.v. arms than the oral arm. Serum CTX levels 
were markedly reduced in all arms. As with the oral 
ibandronate, MOBILE study, a 3-year LTE of DIVA is 
ongoing.42 In the LTE, patients received ibandronate 
i.v. injections 2 mg every 2 months and 3 mg quarterly 
only. Therefore, patients who were previously 
receiving oral ibandronate have been reallocated to an 
i.v. regimen. In the overall study population, further 
BMD increases were seen at the lumbar spine and at 
the hip (interim data at 1 year, 3 years on treatment). 
In addition, a pooled analysis evaluating only those 
patients who remained on the same i.v. treatment for 
3 years showed significant gains in lumbar spine and 
total hip BMD versus baseline (p  0.0001). The 
reduction of serum CTX seen in the 2 years of DIVA 
was maintained in the first year of the LTE.
safety
As with any treatment, the benefits must be considered 
alongside the potential side effects that may be experienced 
by the patient. This is particularly true when 
considering a long-term therapy for a chronic disease, 
such as osteoporosis.
Oral and i.v. ibandronate have been studied at 
various doses and with varying dose-free intervals. 
These regimens have been collectively reviewed to 
obtain an overall safety and tolerability profile. Oral 
(0.25–5 mg daily and 50–150 mg monthly) and i.v. 
(2 mg every 2 months and 0.25–3 mg quarterly) 
ibandronate have demonstrated similar overall 
tolerability profiles to placebo, with a comparable 
number of reported adverse events.20,21,23,29 Although 
not compared directly with placebo, the overall 
tolerability profiles for monthly oral ibandronate 
(150 mg) and quarterly i.v. ibandronate (3 mg), the 
licensed regimens, are similar to daily oral ibandronate 
(2.5 mg; Table 1).32,33,40,41
In clinical practice, orally administered 
bisphosphonates have previously been associated 
with GI intolerance. In the BONE study, the overall 
incidence of GI adverse events was similar with 
ibandronate (daily or intermittent) and placebo.43 
This was also true when GI adverse events reported 
by patients with a history of upper GI disorders 
or patients taking concomitant non-steroidal anti-
inflammatory drugs (NSAIDs) were reviewed. 
Importantly, the incidence of GI adverse events in the 
overall MOBILE study population, and those patients 
taking NSAIDs, was similar with monthly and daily 
oral ibandronate.33
In some patients, i.v. administration of nitrogen-
containing bisphosphonates is associated with a flu-
like illness in the period immediately after dosing;44–47 
although less frequently, similar symptoms have also 
been observed with oral bisphosphonates. Therefore, 
as would be expected, patients receiving monthly 
oral or quarterly i.v. ibandronate in clinical trials have 
reported a slightly higher incidence of flu-like illness 
(including the investigator-reported event terms 
‘influenza-like illness’ and ‘acute-phase reaction’) 
compared with the daily oral regimen.33,41 However, 
these symptoms are generally mild to moderate in 
severity, occur within 3 days of the first dose and 
resolve without treatment, within 7 days.
Renal issues are also commonly associated with 
bisphosphonate i.v. infusion administration and such 
issues have led to the infusion times of some 
bisphosphonates being extended. Interestingly, a pooled 
ibandronate in the management of postmenopausal osteoporosis
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safety database including 3,295 patients receiving 
i.v. ibandronate injection 2–12 mg annually found no 
cases of acute renal failure and no adverse effects on 
indicators of renal toxicity or function.48 Mean CLR 
in patients receiving i.v. ibandronate remained stable 
compared with baseline and was similar to that seen 
in patients receiving oral ibandronate or placebo. 
Marked changes in serum creatinine occurred in only a 
small number of patients, with no dose-response evident. 
Although it has been reported in pharmacokinetic 
studies that the CLR of ibandronate in renally 
impaired patients is lower than in normal subjects,17 
no dose adjustment is necessary for patients with 
mild or moderate renal impairment where CLR 
is 30 mL/min.10,11 Ibandronate is not recommended 
for patients with a CLR  30 mL/min due to limited 
clinical experience. In addition, no adjustment of 
ibandronate dose is required for the elderly or patients 
with hepatic impairment.10,11
Older patients (or = 70 years) receiving oral 
daily and intermittent ibandronate are at no greater 
risk of adverse events than older patients receiving 
placebo. Older patients are at no greater risk of upper 
GI adverse events than younger patients or patients 
receiving placebo.49
A potential side effect associated with 
bisphosphonates is osteonecrosis of the jaw (ONJ). 
The incidence of ONJ in the general population 
is unknown; this rare condition also may occur in 
patients not receiving bisphosphonates. Case reports 
have discussed ONJ development in patients with 
multiple myeloma or metastatic breast cancer receiving 
bisphosphonates as palliation for bone metastasis. 
These patients are also receiving chemotherapeutic 
agents that might impair the immune system and affect 
angiogenesis. The incidence or prevalence of ONJ 
in patients taking bisphosphonates for osteoporosis 
seems to be very rare (1/100000 patients-years). 
No causative relationship has been unequivocally 
demonstrated between ONJ and bisphosphonates 
therapy, including ibandronate. A majority of ONJ 
occurs after tooth extraction. Furthermore, the 
underlying risk of developing ONJ may be increased 
in osteoporotic patients by comorbid diseases.50
Owing to the reported incidence of rhabdomyolysis, 
defined as the combination of muscle pain and creatine 
kinase (CK) elevation 10 times the upper limit of 
normal, associated with statin therapy and following the 
publication of the CK monitoring recommendations,51 
an exploratory study was conducted to characterise 
the CK profile in postmenopausal women treated with 
ibandronate [Data on file, previously unpublished]. 
This study included healthy volunteers (n = 260) 
and assessed the levels of CK during 12 weeks of 
treatment with monthly oral ibandronate (150 mg), 
weekly risedronate (35 mg; control group) and monthly 
placebo. The results of CK monitoring were consistent 
between active drugs and placebo throughout the 
study and no significant change in total serum CK 
level was elicited. These results show that monthly 
oral ibandronate 150 mg is unlikely to trigger an 
unexpected increase in total serum CK level in 
postmenopausal women.9
Efficacy
The goal of osteoporosis treatment is the prevention 
of all fracture types, including both vertebral and 
nonvertebral fractures. While vertebral fracture is the 
Table 1. Summary of adverse event data at 2 years with monthly oral ibandronate 150 mg and quarterly i.v. ibandronate 
3 mg compared with daily oral ibandronate 2.5 mg (%; safety populations).24,32
Mobile Diva
  2.5 mg daily 
(n = 395)
150 mg monthly 
(n = 396)
2.5 mg daily 
(n = 465)
3 mg quarterly 
(n = 469)
Any Ae 76.5 80.1 87.7 85.3
Any drug-related Ae 32.4 36.9 36.8 42.0
 Leading to withdrawal 7.6 6.8 6.0 6.5
Any serious Ae 9.6 11.4 14.4 13.2
Any serious drug-related Ae 0.5 0.3 0.9 0.4
 Leading to withdrawal 0.3 0.3 0.4 0
Abbreviation: Ae, adverse event.
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most common osteoporotic fracture type, nonvertebral 
fractures such as those of the hip can be the most 
debilitating and costly. Thus the global assessment 
of efficacy of an anti-osteoporosis treatment requires 
an extensive evaluation of its anti-fracture efficacy 
at all skeletal-sites. Similarly, no prospective head-
to-head trials, comparing the anti-fracture efficacy of 
the currently marketed bisphosphonates have been 
conducted, due to the large sample size such studies 
would require to reliably detect differences in fracture 
risk, and the associated high cost.52 Therefore, a valid 
assessment of the efficacy of a new bisphosphonate 
can be based on observational database analysis, 
which can provide sufficient sample size and permit 
the comparison of marketed doses in current clinical 
practice, allowing the evaluation of agents in a 
population with a broader range of characteristics than 
is typically permitted in a randomized clinical trial. 
Well-designed observational database studies have an 
important place in evidence-based medicine and can 
be used to compare the effects of bisphosphonates 
on clinical outcomes such as the risk of fracture.
Two meta-analyses to assess the anti-fracture 
efficacy of different doses of ibandronate have 
recently been completed utilizing slightly different 
methodologies. The first meta-analysis, conducted 
by a Canadian-based group and supported by a wider 
team of osteoporosis experts (Steering Committee for 
IbandronatE and Non-vertebral fraCture Endpoints: 
SCIENCE), used individual patient data from 
MOBILE32,33 and DIVA,40,41 trials of similar design, to 
assess the effect of different doses of ibandronate on 
non-vertebral fractures.53 The varying doses used in the 
two studies were grouped based on annual cumulative 
exposure (ACE = dose × dose frequency/year × 
absorption factor e.g. 150 mg × 12 × 0.006 = 10.8 mg). 
This analysis showed a relative risk reduction in 
non-vertebral fracture rate of 38% when comparing 
combined doses (including monthly oral ibandronate 
150 mg, quarterly i.v. ibandronate 3 mg and i.v. 
ibandronate 2 mg every 2 months [not licensed]) 
equivalent to an ACE of 10.8 mg with an ACE of 
5.5 mg (2.5 mg daily ibandronate). A dose-response 
effect was noted with increasing ACE (7.2–12 mg) 
compared with ACE 5.5 mg.
The second meta-analysis utilized individual 
patient data from four pivotal phase III clinical trials 
(i.v. dose fracture study,29 BONE,29 MOBILE,32,33 
and DIVA),30,32 all of which have been discussed 
individually above.54 BONE and the i.v. dose fracture 
study were 3-year placebo-controlled fracture trials; 
MOBILE and DIVA were 2-year BMD active-
comparator studies, which collected fracture data as 
safety measurements. Similar to the Canadian analysis, 
annual doses were grouped by ACE, i.e. high 
(10.8 mg includes 150 mg oral monthly, 3 mg 
i.v. quarterly, and 2 mg i.v. every 2 months), mid 
(5.5–7.2 mg) and low (4.0 mg). However, rather 
than comparing to the low ibandronate dose group, 
this analysis compared reductions in fracture risk to 
placebo, using a combined placebo group from BONE 
and the i.v. dose fracture study. It was observed that 
the risk of clinical (vertebral and non-vertebral) and 
non-vertebral fractures was significantly reduced 
for doses of ibandronate with an ACE of 10.8 mg 
compared with placebo. A significant reduction in risk 
associated with ibandronate was also demonstrated 
for a subgroup of six major non-vertebral fractures 
(clavicle, humerus, wrist, pelvis, hip and leg).
Based on the review of the efficacy profile of 
ibandronate summarized here, the evidence clearly 
supports the use of monthly oral ibandronate (150 mg) 
and quarterly i.v. injection ibandronate (3 mg) for the 
treatment of postmenopausal osteoporosis.
A meta-analysis pooled data from the four 
phase III clinical trials of ibandronate to assess the 
relationship between ibandronate dose, changes 
in bone mineral density, and rates of both clinical 
and non-vertebral fractures. Individual patient data 
from the intent-to-treat population of the BONE, 
IV fracture prevention, MOBILE, and DIVA studies 
were included for analysis. The relationship between 
ibandronate dose and bone mineral density at both 
the lumbar spine and at the total hip was assessed 
qualitatively. The relationship between lumbar spine 
bone mineral density and clinical fracture rate, and the 
relationship between total hip bone mineral density 
and non-vertebral fracture rate, were assessed both 
qualitatively and using mathematical models. A total 
of 8710 patients were included in this analysis. Both 
lumbar spine and total hip bone mineral density were 
observed to increase with increasing ibandronate 
dose. The incidence of all clinical fractures was 
observed to decrease as lumbar spine bone mineral 
density increased. A statistically significant inverse 
linear relationship was observed between percent 
ibandronate in the management of postmenopausal osteoporosis
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change in lumbar spine bone mineral density and the 
rate of clinical fractures (P = 0.005). A non-significant 
curvilinear relationship was observed between percent 
change in total hip bone mineral density and non-
vertebral fracture rate. The authors concluded that 
increased ibandronate exposure is associated with 
increasing gains in the lumbar spine bone mineral 
density and decreasing clinical fracture rates and that 
a non-linear relationship may exist between increases 
in the total hip bone mineral density and non-vertebral 
fracture rate.55
Although the efficacy of ibandronate had been 
demonstrated in clinical trials, alongside patient 
preference and adherence, ‘real life’ efficacy was still 
to be confirmed.
The eValuation of IBandronate Efficacy (VIBE) 
head-to-head database fracture study compared 
fracture rates between patients treated with monthly 
ibandronate and weekly oral bisphosphonates (BPs). 
This large study included women /= 45 years 
old, newly prescribed monthly oral ibandronate or 
weekly oral alendronate or risedronate, and without 
malignancy or Paget’s disease of bone. The primary 
analysis included patients who were adherent to 
treatment during the first 90 days after the index 
date. The risks of hip, nonvertebral, vertebral and 
any clinical fracture were compared using Cox 
proportional hazards models and adjusted for 
potential confounding factors. A secondary, “intent-
to-treat” analysis included all patients who received 
at least one BP prescription. Sensitivity analyses 
based on the primary analysis compared patients 
receiving ibandronate with patients receiving weekly 
alendronate or risedronate separately, and explored the 
effect of excluding patients with potential confounding 
factors from the analysis. Further sensitivity analyses 
varied the requirement for adherence during the first 
90 days after the index date. The primary analysis 
population included 7345 monthly ibandronate 
and 56,837 weekly BP patients. Fracture rates after 
the 12-month observational period were 2% and 
fracture risk was not significantly different between 
patients receiving monthly ibandronate or weekly BPs 
for hip, nonvertebral or any clinical fracture (adjusted 
relative risk: hip = 1.06, p = 0.84; nonvertebral = 
0.88, p = 0.255; any clinical fracture = 0.82, p = 0.052). 
Ibandronate patients had a significantly lower 
risk of vertebral fracture than weekly BP patients 
(adjusted relative risk 0.36, 95% confidence interval 
0.18–0.75, p = 0.006). In the secondary, “intent-to-
treat” analysis, relative risks of fracture were not 
significantly different between treatment groups for 
any fracture type. The results of the sensitivity analyses 
were generally consistent with the primary analysis. 
This retrospective cohort study found that patients 
treated with oral monthly ibandronate or weekly BPs 
(alendronate and risedronate) had similar, low risks 
of hip fracture, nonvertebral fracture and any clinical 
fracture. Ibandronate patients had a significantly 
lower relative risk of vertebral fracture than weekly 
BP patients; the clinical implications of these findings 
require further exploration and validation.56
patient preference
Randomised, controlled clinical trials are most 
frequently used to determine the efficacy and safety 
of a new drug or regimen. However, they do not 
describe how a regimen is perceived by patients, 
and therefore, the acceptability and use of a drug in 
clinical practice. Patient adherence to therapy for the 
treatment of chronic disease is poor; this is also true 
for oral bisphosphonates used to treat postmenopausal 
osteoporosis.57 A study of 211,319 women receiving 
a prescription for a daily or weekly bisphosphonate 
(alendronate or risedronate) found that, following a 
steady decline throughout the 12-month study period, 
only 39% of patients receiving a daily regimen and 
57% of patients receiving a weekly regimen were 
continuing treatment at the end of the study.58 The 
consequences of poor adherence can be severe. 
A database study of 35,537 women receiving a 
bisphosphonate prescription reported that compliant 
patients, that is, those patients who had medication 
available for 80% of the study, had a 21% lower 
fracture rate than those patients considered to be non-
compliant (p  0.001).59 The adjusted risk was also 
significantly lower in compliant versus non-compliant 
patients when non-vertebral and hip fractures were 
considered separately (20% and 37%, respectively; 
p  0.001 for both). An exhaustive search of the 
Belgian national social security database conducted 
in postmenopausal women, naïve to bisphosphonates, 
who received the first prescription of alendronate 
assessed the impact of persistence on hip fracture 
risk, using the Cox proportional hazards model. 
At 12 months, the rate of persistence was 39.45%.
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For each decrease of the Medication Possession 
Ratio by 1%, the risk of hip fracture increased by 
0.4% (OR: 0.996; CI 95%: 0.994–0.998; p  0.001). 
The relative risk reduction for hip fracture was 60% 
(HR: 0.404; CI 95%: 0.357–0.457; p  0.0001) for 
persistent compared to non-persistent patients.60
The impact of a reducing bisphosphonate dosing 
frequency on therapeutic adherence has been documented 
in several studies. Data have shown that, although 
weekly dosing improves adherence compared to daily 
administration, levels are still suboptimal.61
Studies to assess adherence with the monthly 
oral ibandronate regimen have also been conducted. 
An open-label study and a database study including 
two databases (i3 Innovus and HealthCore) have 
compared monthly ibandronate with weekly 
bisphosphonates, alendronate and risedronate, and 
both studies reported improved rates of persistence 
with the monthly regimen.62,63 In the UK, open-label 
study (n = 1,103), a 47% relative improvement in 
persistence was reported for the monthly ibandronate 
group versus weekly alendronate (p  0.0001).62 
As per standard clinical practice in the UK, patients 
in the ibandronate group were enrolled into a patient 
support programme. The database study included a 
total of 3,512 and 13,967 women prescribed monthly 
ibandronate or weekly bisphosphonates, respectively, 
from the i3 Innovus claims database and 1,006 and 
10,658 patients, respectively, from the HealthCore 
database.63 After adjusting for age, co-pay and 
co-morbidities, monthly users were 25% and 38% less 
likely to discontinue therapy versus weekly users in 
the i3 Innovus and HealthCore analyses, respectively. 
Other persistence database studies comparing monthly 
and weekly bisphosphonate regimens have been 
completed.64,65 However, it is likely that differences 
in methodology, such as a lack of adjustment for 
confounding variables and not tailoring the refill gap 
for individual regimen dosing windows, have led 
to varying results from those summarized above.61
To further characterize the reported improved 
adherence with monthly versus weekly bisphosphonate 
regimens an open-label study (PRIOR) enrolled 
patients (n = 543) who had discontinued daily or 
weekly alendronate or risedronate due to perceived or 
actual GI intolerance.66 On entering the study, patients 
were given the choice of receiving either monthly 
oral or quarterly i.v. ibandronate. Interestingly, 27% of 
patients chose oral ibandronate and 73% of patients 
chose the i.v. regimen. Adherence rates were similar 
between both regimens (70% in the oral group and 83% 
in the i.v. group). Study patients reported a significant 
improvement in GI symptoms compared with baseline 
while receiving either form of ibandronate (p  0.0001 
for both). Another adherence study, BOHEMIA, 
assessed the impact of providing biofeedback, using 
bone turnover markers, on adherence in patients 
receiving monthly ibandronate (n = 781).67 High 
adherence was reported in both study groups, those 
receiving biofeedback and those who were not (95% 
CI: 98.8%–99.8% and 95.5%–97.5%, respectively). 
When the two groups were compared, a statistically 
significant difference in favour of biofeedback was 
noted (p  0.001).
In addition to treatment efficacy and possible 
side effects, patient preference is also likely to 
impact on long-term therapeutic adherence. In two 
6-month, randomised, crossover, open-label studies 
(iBandronate ALendronate Trial in Osteoporosis: 
BALTO I and II) including a total of  692 patients, 70% 
of patients expressed a preference for the monthly 
oral ibandronate regimen versus the weekly 
alendronate regimen (p  0.0001) and ~75% stated 
that the monthly ibandronate regimen was more 
convenient than the weekly alendronate regimen 
(p  0.0001).68,69 The most common reasons for 
preferring the monthly regimen were greater ease of 
following the treatment regimen for a long-time and 
better lifestyle fit.
place in Therapy
Since the mid-eighties, the management of osteoporosis 
has dramatically changed, from treatments that were 
either lacking anti-fracture efficacy (e.g. fluoride salts 
and etidronate) or linked to significant morbidity (e.g. 
estrogens), to new molecules combining reduction in 
fractures rates at various skeletal sites and positive risk-
benefit ratios. Practitioners now have the opportunity 
to offer their patients a wide variety of appropriate 
treatments. However, most of the treatments developed 
between 1990 and 2000 were linked with poor adherence. 
Since adherence to therapy is a major determinant 
of the final outcome of drug management, the 
levels of benefit observed in real-life settings were 
quite different from those reported in randomised 
controlled trials. Subsequently, new chemical entities 
ibandronate in the management of postmenopausal osteoporosis
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were developed with the final objective of meeting 
patient’s needs.70
In the field of osteoporosis management and 
bisphosphonates, the most widely prescribed 
osteoporosis drugs worldwide, large surveys have 
identified adverse events and discomfort linked to 
regular intake of medication as the major drawbacks 
leading to poor adherence. Ibandronate was the first 
bisphosphonate for which anti-fracture efficacy had 
been unequivocally shown with dosing intervals greater 
than weekly. The monthly oral and quarterly IV injection 
formulations display anti-fracture efficacy similar to 
that obtained with daily or weekly oral bisphosphonates 
(i.e. alendronate and risedronate). Whereas the pivotal 
ibandronate study (BONE) concentrated on patients 
at high-risk of vertebral fractures, further analyses, 
including meta-analyses and real-life setting databases, 
have confirmed that the currently marketed doses (i.e. 
150 mg monthly oral and 3 mg quarterly IV injection) 
have a positive effect on non-vertebral fractures, to 
the same extent as previously seen at the spine.
Adherence to treatment has been significantly 
improved (up to 51%) with monthly compared 
with weekly or daily administration of oral 
bisphosphonates,46,47 hence providing a solution to one 
of the major challenges in bisphosphonate management 
of osteoporosis.
conclusions
Intermittent ibandronate with dose-free intervals 
of more than one week can be administered either 
orally or as an i.v. injection and therefore provides a 
new solution to the management of postmenopausal 
osteoporosis. Intermittent oral therapy is convenient 
and offers patients independence from close supervision, 
which benefits them, their physicians and the health 
services. Some patients, however, may need or 
prefer i.v. therapy perhaps because they are bed-
bound or otherwise unable to follow strict dosing 
instructions. In such cases, an injection may be 
preferable to a prolonged infusion as it is likely to 
be less prone to complications. Thus availability of 
intermittent regimens of both oral and i.v. ibandronate 
is expected to provide physicians with the option of 
being able to tailor therapy to the needs of individual 
patients. These simple intermittent ibandronate dosing 
schedules are expected to optimally combine efficacy, 
tolerability and patient convenience. Their availability 
should help optimize osteoporosis management in the 
21st century.
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